Heart Failure Medication The purpose of the article by Gordin and Fonarow (2016) entitled “New Medications for Heart Failure” is to examine and discuss established guidelines for medical treatment for heart failure. Specifically, the article examines pharmacological interventions for heart failure with regard to ACE inhibitors, beta blockers, aldosterone antagonists and reduced ejection fraction. It looks at recent studies that have allowed new therapeutic methods to be developed using ivabradine and valsartan, the former of which decreases heart rate and the latter of which elevates vasodilatory peptides that have an angiotensin receptor antagonist. The article was chosen because it is timely and evaluates the “first new-in-class medications” designed to further help provide quality care for patients suffering from heart failure (Gordin & Fonarow, 2016, p. 491). By examining several trials conducted for the drugs, the study shows that both ivabradine and valsartan are effective in decreasing hospitalizations for patients with heart failure. The trials referenced in the study include: the PARADIGM-HF trial, which found that valsartan helped to thwart the advance of heart failure much better than patients who were treated with enalapril; and the SHIFT trial, which showed that ivabradine improved heart failure...
Gordin and Fonarow (2016) indicate that both ivabradine and valsartan may be used as part of a treatment plan for heart failure patients in the future for patients with heart rate at rest of 70 bpm or more. For the purposes of developing a treatment plan,t he study identifies the brand names of these drugs (Corlanor and Entresto, respectively), describes their FDA-approved purposes, the proper dosage for patients and associated goals, when to stop dosage, and the adverse side effects to watch out for, such as hypotension, renal impairment and cough for valsartan (Entresto) and hypertension, bradycardia and atrial fibrillation for ivabradine (Corlanor).References
Bas, H. D., Baser, K., & Nair, N. (2017). Updates on management of advanced heart failure. The Southwest Respiratory and Critical Care Chronicles, 5(20), 12-21.
Gordin, J. & Fonarow, G. (2016). New medications for heart failure. Trends in Cardiovascular Medicine, 26, 485-492.
Heart Failure Guidelines The 2009 revision of the ACC/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults contains a number of evidence-based updates, revised text, and a new section called "hospitalized patient" (Hunt et al. e395). These revisions are the result of a task force that convened in 2008 and represent new findings published between 2005 and 2008. Four stages along a continuum of heart failure are described, with
Heart failure has been described as a "complex clinical syndrome that results from either structural or functional impairment of ventricular filling or ejection," (Alspach, 2014, p. 1). Because of the multifaceted nature of heart failure, it is important to recognize its various symptoms and dimensions. Heart failure in general presents a major public health concern, with current prevalence at over five million adults in the United States and over 650,000
safe Transition • in October 2012, made Medicare payment rules. Hospitals penalized a patient returns 30 days treatment problem. One targeted medical diagnoses payment change heart failure (HF). Making a safe transition Heart failure medication Medications used to treat heart failure and why they are used Beta adrenergic blockers, diuretics and ACE inhibitors are some of the common classes of drugs used to manage heart failure. Beta adrenergic blockers are used because they
M.K., a 45-year-old female who has a history of Type II diabetes mellitus and primary hypertension. In addition to this, M.K. is overweight and persists with a poor diet. The patient has also been smoking for the past 22 years, and has recently been diagnosed with chronic bronchitis. Current symptoms include chronic cough, which tends to be more severe in the mornings and productive with sputum, light-headedness, distended neck
Treatment of Heart Failure in Nursing Home Residents Heart failure (HF) symptoms may occur because of systemic and pulmonary congestion, structural defects arising on account of HF, structural defects leading to HF, or from treatment complications. At first, studies addressing the issue of heart failure focused on HF patients and decreased left ventricular contraction. As a result, therapies were tested within this patient cluster. This patient cluster's agreed description is HF
PICOT Analysis on Chronic Heart Failure One may describe heart failure (HF) as a complicated medical condition which may arise due to functional or structural cardiac disorders capable of hindering ventricular capability of ejecting or filling blood. Chronic HF (CHF) represents a serious health issue. Its prevalence in America stands at over 5.8 million, while over 23 million individuals across the globe are affected by this problem. The mortality rate linked
Our semester plans gives you unlimited, unrestricted access to our entire library of resources —writing tools, guides, example essays, tutorials, class notes, and more.
Get Started Now